# **Special Issue**

# Circulating Tumor Cells (CTCs) for Cancer Diagnosis and Prognosis

# Message from the Guest Editor

The study of circulating tumor cells (CTCs) has emerged as one of the most promising areas in precision oncology, offering valuable insights into tumor biology, metastatic dissemination, and treatment response. This Special Issue of Cancers focuses on recent advances in the molecular and technological analysis of CTCs, as well as their applications in cancer diagnosis, prognosis, and disease monitoring. Particular emphasis is placed on innovative approaches for CTC isolation and characterization, the investigation of genomic and epigenetic alterations associated with disease progression, and the use of CTCs as a liquid biopsy tool to guide personalized therapy. In parallel, the combined analysis of CTCs and circulating cell-free DNA (cfDNA) represents a powerful strategy to obtain a more comprehensive picture of tumor heterogeneity and evolution, enhancing the sensitivity and specificity of liquid biopsy-based diagnostics. We welcome original research and review articles that highlight the translational potential of CTCs, alone or in combination with cfDNA, bridging the gap between basic science and clinical practice and contributing to improved patient management and outcomes.

### **Guest Editor**

Dr. Athina N. Markou

Department of Chemistry, National and Kapodistrian University of Athens, 15771 Athens, Greece

### Deadline for manuscript submissions

31 October 2026



# **Cancers**

an Open Access Journal by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



mdpi.com/si/258132

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

mdpi.com/journal/cancers





# **Cancers**

an Open Access Journal by MDPI

Impact Factor 4.4 CiteScore 8.8 Indexed in PubMed



# **About the Journal**

# Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

## **Editor-in-Chief**

Prof. Dr. Samuel C. Mok.

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

# **Author Benefits**

# **Open Access:**

free for readers, with article processing charges (APC) paid by authors or their institutions.

# **High Visibility:**

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

### Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)

